Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head|
- Resectability rate > 70% after restaging [ Time Frame: 2007 ]
|Study Start Date:||October 2001|
|Study Completion Date:||May 2007|
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.
Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.
- Trial with medicinal product
Please refer to this study by its ClinicalTrials.gov identifier: NCT00490360
|University Hospital of Zurich, Department of Surgery|
|Study Director:||01 Studienregister MasterAdmins||UniversitaetsSpital Zuerich|